Lexi Webster
DMAA (1,3-dimethylamylamine), a substance sometimes used in pre-workout sports supplements, was banned in Australia in 2012. The Therapeutic Goods Administration (TGA) prohibited the sale, supply, and use of DMAA, classifying it as a prohibited substance due to safety concerns and lethal side effects. This decision followed similar bans in other countries and positive tests for DMAA in Australian athletes. The ban on DMAA in Australia has sparked debates about the potential adverse health effects of the substance and the impact of prohibition policies.
| Characteristics | Values |
|---|---|
| Date of ban in Australia | 8 August 2012 |
| Name of banned substance | 1,3-dimethylamylamine (also known as methylhexaneamine) |
| Common name | DMAA |
| Type of substance | Pharmaceutical derivative, stimulant, vasoconstricting substance |
| Previous use | Nasal inhaler, sports supplements, party pills |
| Reason for ban | Safety concerns, adverse health effects, lethal side effects |
| Risks associated with use | High blood pressure, psychiatric disorders, bleeding in the brain, stroke, headaches, vomiting, death |
| Regulatory body | Therapeutic Goods Administration (TGA) |
| Regulatory action | Banned sale, supply, and use; included in Appendix C of poisons standard |
| International bans | New Zealand, Canada, United States |
Explore related products
What You'll Learn
DMAA is a stimulant with lethal side effects
DMAA, or 1,3-dimethylamylamine, is a stimulant that has been linked to several lethal side effects. It was first introduced in 1948 as a nasal inhaler to alleviate irritation and inflammation of the mucous membranes inside the nose. While it was withdrawn in the 1970s due to concerns about its efficacy, it has since been used in various sports supplements.
DMAA has been marketed as a safe, naturally occurring substance, but this claim has been refuted by recent studies. It has been associated with several adverse health consequences, including high blood pressure, psychiatric disorders, bleeding in the brain, and stroke. In 2011, it was identified in the toxicology reports of two United States Army soldiers who died. Additionally, a New Zealand man who ingested 'party pills' containing DMAA suffered a cerebral hemorrhage.
Due to these serious health concerns, DMAA was banned in Canada in 2011 and has since been banned or heavily restricted in other countries, including New Zealand, the United States, and Australia. In June 2012, the Advisory Committee on Medicines Scheduling in Australia proposed including DMAA in Schedule 9 ('Prohibited Substances') of the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). The Therapeutic Goods Association (TGA) ultimately included DMAA in Appendix C of the SUSMP, noting that it has no accepted therapeutic use and can lead to significant adverse events.
The decision to ban the sale, supply, and use of DMAA in Australia highlights the potential dangers of this stimulant. It is important for consumers to be aware of the risks associated with DMAA and to seek alternative, safer options for their health and fitness goals.
Discount Rates: Australia's Current Climate
You may want to see also
Explore related products
DMAA was banned in Australia in 2012
DMAA, or 1,3-dimethylamylamine, is a pharmaceutical derivative that was first introduced in 1948 as a nasal inhaler. In June 2012, it was banned in Australia, becoming a scheduled substance in the country. The decision to ban DMAA was made by the Therapeutic Goods Administration (TGA), which cited concerns over its lethal side effects as the primary reason for the prohibition.
Prior to the ban, DMAA was a popular ingredient in sports supplements, often marketed as a natural substance. It was used to provide athletes with extra energy and an adrenaline-like high. However, its use was also associated with serious adverse health consequences, including high blood pressure, headaches, vomiting, stroke, and even death.
The TGA's decision to ban DMAA was not an isolated incident. Several other countries, including New Zealand, Canada, and the United States, had already taken similar steps to prohibit or heavily restrict the substance. In 2010, the World Anti-Doping Agency (WADA) also added DMAA to its list of prohibited substances, after nine Australian athletes tested positive for its presence.
The ban on DMAA in Australia went into effect on August 8, 2012. The TGA worked with Australian Customs and Border Protection Services to stop future shipments of products containing DMAA from entering the country. This collaborative effort ensured the effective implementation of the ban and protected Australian consumers from the potentially harmful substance.
Airlines Flying from Australia to Japan: Comprehensive Guide
You may want to see also
Explore related products
DMAA was included in sports supplements
DMAA, or 1,3-dimethylamylamine, is a pharmaceutical derivative that was first introduced in 1948 as a nasal inhaler to alleviate irritation and inflammation of the mucous membrane inside the nose. While it was approved for this use, its medical efficacy was later questioned, and approval was withdrawn in the 1970s. More recently, DMAA has been used in various sports supplements, such as Jack3d®, under the guise of being a naturally occurring substance.
In 2010, DMAA was placed on the World Anti-Doping Agency's (WADA) list of prohibited substances. This decision was made due to the substance's potential performance-enhancing effects and health threats. Following this, several countries, including Canada and New Zealand, banned or heavily restricted the use of DMAA.
In June 2012, Australia followed suit, and DMAA became a scheduled substance. The Therapeutic Goods Administration (TGA) banned the sale, supply, and use of DMAA, and it was included in Appendix C of the poisons standard, the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). This decision was made due to concerns over the substance's lethal side effects, including high blood pressure, headaches, vomiting, stroke, and even death.
The ban on DMAA in sports supplements in Australia was enforced on August 8, 2012. The TGA worked with Australian Customs and Border Protection Services to stop future shipments of products containing DMAA from entering the country. This was done to protect public health and ensure the safety of consumers.
Converting Australian Dollars to US Dollars: How Much is it?
You may want to see also
Explore related products
DMAA was placed on WADA's prohibited substances list in 2010
DMAA, or 1,3-dimethylamylamine, is a pharmaceutical derivative that was first introduced in 1948 as a nasal inhaler to alleviate irritation and inflammation of the mucous membrane inside the nose. While approval for the substance was withdrawn in the 1970s, it has since been used in various sports supplements.
In 2010, the World Anti-Doping Agency (WADA) added DMAA to its Prohibited List, which is the comprehensive document serving as the international standard for identifying substances and methods prohibited in sport. This decision was made because DMAA met two of the three criteria for inclusion: it had the potential to enhance sports performance, and it represented an actual or potential health risk to the athlete.
Indeed, DMAA has been implicated in several serious adverse health consequences. For example, it was identified in the toxicology reports of two United States Army soldiers who died in 2011, and a New Zealand man who ingested DMAA "party pills" suffered a cerebral hemorrhage.
Following DMAA's addition to WADA's Prohibited List, it was banned in several countries, including Canada in 2011 and New Zealand in 2012. In Australia, DMAA was not a scheduled substance before 2012. However, in June 2012, the Advisory Committee on Medicines Scheduling proposed including DMAA in Schedule 9 ("Prohibited Substances") of the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). This proposal was met with some opposition, but ultimately, the Therapeutic Goods Association (TGA) included DMAA in Appendix C of the SUSMP, noting that it had no accepted therapeutic use, could have stimulant and psychoactive effects, was promoted as a "party drug", and had been associated with a number of significant adverse events. As a result, sports supplements containing DMAA were banned in Australia.
Understanding Australia's Westminster System of Government
You may want to see also
Explore related products
DMAA has been linked to high blood pressure, vomiting, stroke and death
DMAA (1,3-dimethylamylamine) is a pharmaceutical derivative first introduced in 1948 as a nasal inhaler to alleviate irritation and inflammation of the mucous membrane inside the nose. It was withdrawn in the 1970s as its efficacy was questioned. DMAA has since been used in sports supplements, marketed as a "natural" stimulant for performance enhancement and weight loss.
DMAA has been banned in several countries, including Australia, due to safety concerns. It is a stimulant and vasoconstrictor, narrowing blood vessels and arteries, which can lead to increased blood pressure and serious cardiovascular problems. The FDA advises against its use and considers it an unsafe food additive.
DMAA has been linked to several adverse health effects, including liver injury, cardiac arrest, and stroke. It has also been associated with hemorrhagic stroke, as seen in a New Zealand man who ingested 'party pills' containing DMAA. Additionally, DMAA was identified in the toxicology reports of two US Army soldiers who died in 2011. The pressor action of DMAA, especially when combined with caffeine, may contribute to these adverse effects.
In Australia, DMAA became a scheduled substance in June 2012, following proposals from the Advisory Committee on Medicines Scheduling. This decision was made due to the substance's lack of accepted therapeutic use, stimulant effects, promotion as a 'party drug', and reports of significant adverse events. The ban on DMAA in Australia aims to protect consumers from the potential health risks associated with its use.
Halogen Lights: Australia's Ban and Its Reasoning
You may want to see also
Frequently asked questions
DMAA, or 1,3-dimethylamylamine, is a pharmaceutical derivative first introduced in 1948 as a nasal inhaler to alleviate irritation and inflammation of the mucous membrane inside the nose.
Yes, DMAA was banned in Australia in August 2012. The Therapeutic Goods Administration (TGA) banned the sale, supply, and use of DMAA.
DMAA was banned in Australia because of concerns that it could have lethal side effects. It has been linked to side effects including high blood pressure, headaches, vomiting, stroke, and death.
